Chronic Infantile Neurological Cutaneous Articular Syndrome - 8 Studies Found
Terminated |
: Canakinumab to Treat Neonatal-Onset Multisystem Inflammatory Disease :
: 2008-10-09 : Drug: Canakinumab |
Completed |
: Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease :
: Drug: Canakinumab (ACZ885) 6 mL glass vial containing 150 mg lyophilized Canakinumab reconstituted with |
Terminated |
: Anakinra to Treat Patients With Neonatal Onset Multisystem Inflammatory Disease :
|
Completed |
: Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease :
: Drug: ACZ885 |
Completed |
: Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase :
: Drug: canakinumab canakinumab |
Terminated |
: HL2351 CAPS Phase II Study : Cryopyrin‑Associated Periodic Syndromes (CAPS) : 2016-05-10 : Drug: HL2351 The dose will be adjusted based on disease activities |
Completed |
: The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada : Cryopyrin Associated Periodic Syndrome : 2010-03-25 : Drug: canakinumab (company code: ACZ885D) |
Completed |
: Clinical Outcomes and Safety: A Registry Study of Ilaris (Canakinumab) Patients :
|